EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)

GLASGOW, Scotland, April 03, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the first patient has been dosed in a multi-centre randomised double-blind placebo…#glasgow #scotland #enterobiotixlimited #ibs #unitedkingdom #functionalgutclinic #amplatm #gmp #jamesmcilroy #enterobiotix
Source: Reuters: Health - Category: Consumer Health News Source Type: news